NG9 Stock Chart & Stats
€13.86
€0.29(2.36%)
At close: 4:00 PM EDT
€13.86
€0.29(2.36%)
Day’s Range― - ―
52-Week Range€6.20 - €17.26
Previous CloseN/A
Volume0.00
Average Volume (3M)142.00
Market Cap
€2.18B
Enterprise Value€2.21K
Total Cash (Recent Filing)€145.54M
Total Debt (Recent Filing)€448.37M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Nov 10, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.98
Shares Outstanding128,475,430
10 Day Avg. Volume20
30 Day Avg. Volume142
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)0.36
Price to Sales (P/S)0.41
P/FCF Ratio-13.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€16.10Price Target Upside16.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)0.15
Revenue Forecast (FY)€689.81M
Bulls Say, Bears Say
Bulls Say
Clinical And NGS GrowthStrong clinical expansion supports NeoGenomics’ core oncology diagnostic franchise, while rapid NGS growth increases exposure to higher-complexity testing. Continued adoption, broader panels, and rising average unit prices can sustain revenue growth and strengthen the company’s competitive position over coming quarters.
Margin And EBITDA ExpansionBroad margin improvement indicates operating leverage from better test mix and execution rather than growth alone. Higher adjusted EBITDA guidance provides evidence that efficiency initiatives are converting revenue gains into stronger earnings capacity, improving the path toward sustainable profitability.
Improving Liquidity And Cash GenerationA substantial cash balance and positive quarterly operating cash flow provide funding for laboratory investment, commercial expansion, and product development. The refinancing also extends the maturity profile, giving the company greater flexibility while its operating improvements continue to develop.
Bears Say
Persistent Operating LossesNeoGenomics has not yet demonstrated consistent profitability or self-funded growth. Negative operating and net margins, combined with slightly negative free cash flow, could constrain reinvestment and leave earnings sensitive to reimbursement, volume, and execution improvements.
Pharma And Nonclinical WeaknessWeakness in the pharma and nonclinical business reduces diversification beyond patient-care testing and offsets some clinical momentum. Although the segment is smaller, prolonged revenue declines could delay recovery in the broader service portfolio and make growth more dependent on clinical testing.
RaDaR Commercialization Depends On ReimbursementRaDaR ST has meaningful longer-term potential, but current revenue remains modest and scaling depends on external reimbursement decisions. Pending submissions and private-payer coverage create execution uncertainty, potentially delaying product adoption and limiting near-term contribution to growth.
NeoGenomics News
NG9 FAQ
What was NeoGenomics’s price range in the past 12 months?
NeoGenomics lowest stock price was €6.20 and its highest was €17.26 in the past 12 months.
What is NeoGenomics’s market cap?
NeoGenomics’s market cap is €2.18B.
When is NeoGenomics’s upcoming earnings report date?
NeoGenomics’s upcoming earnings report date is Nov 10, 2026 which is in 41 days.
How were NeoGenomics’s earnings last quarter?
NeoGenomics released its earnings results on Jul 28, 2026. The company reported €0.043 earnings per share for the quarter, beating the consensus estimate of €0.029 by €0.014.
Is NeoGenomics overvalued?
According to Wall Street analysts NeoGenomics’s price is currently Undervalued.
Does NeoGenomics pay dividends?
NeoGenomics does not currently pay dividends.
What is NeoGenomics’s EPS estimate?
NeoGenomics’s EPS estimate is 0.05.
How many shares outstanding does NeoGenomics have?
NeoGenomics has 128,475,430 shares outstanding.
What happened to NeoGenomics’s price movement after its last earnings report?
NeoGenomics reported an EPS of €0.043 in its last earnings report, beating expectations of €0.029. Following the earnings report the stock price went up 6.187%.
Which hedge fund is a major shareholder of NeoGenomics?
Currently, no hedge funds are holding shares in DE:NG9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeoGenomics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€16.10 (16.13% Upside)
€16.10 (16.13% Upside)
Blogger Sentiment
Bullish
DE:NG9 Sentiment 100%
Sector Average 64%
Sector Average 64%
Insider Transactions
Sold Shares
Worth €282.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
143.25%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.99%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
NeoGenomics
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
NG9 Company Deck
NG9 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed solid commercial and margin momentum driven by strong NGS and clinical performance, operational efficiencies from the Lab of the Future program, and constructive guidance and capital structure actions. Headwinds were concentrated in the smaller nonclinical/pharma segment (notably a 26% decline in Pharma revenue) and timing-sensitive items (reimbursement for RaDaR ST, a DOJ settlement impact, and a tougher Q3 comp from exiting a high-volume low-value contract). Overall, the company demonstrated durable clinical growth, margin expansion and strengthened liquidity while acknowledging discrete near-term challenges that management plans to address.View all DE:NG9 earnings summariesNG9 Stock 12 Month Forecast
Average Price Target
€16.10
▲(16.13% Upside)
Technical Analysis
Labcorp Holdings
―
Quest Diagnostics
―
Veracyte
―
Guardant Health
―
Castle Biosciences
―